Detroit, MICHIGAN9 Active Studies

Breast Cancer Clinical Trials in Detroit, MICHIGAN

Find 9 actively recruiting breast cancer clinical trials in Detroit, MICHIGAN. Connect with local research sites and explore new treatment options.

9
Active Trials
8
Sponsors
2,910
Enrolling

Recruiting Breast Cancer Studies in Detroit

RecruitingDetroit, MICHIGANNCT05296798

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxan...

922 participants
Hoffmann-La Roche
View Study Details
RecruitingDetroit, MICHIGANNCT06757634

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant and CDK4/6 Inhibitors for the treatment of patients with locally advanced o...

674 participants
Celcuity Inc
View Study Details
RecruitingDetroit, MICHIGANNCT04482309

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors. This study...

468 participants
AstraZeneca
View Study Details
RecruitingDetroit, MICHIGANNCT05894239

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination wit...

230 participants
Hoffmann-La Roche
View Study Details
RecruitingDetroit, MICHIGANNCT05607004

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

This open-label research study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer. (Z)-endoxifen belongs to a group of drugs called selective estro...

214 participants
Atossa Therapeutics, Inc.
View Study Details
RecruitingDetroit, MICHIGANNCT05735080

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to eval...

150 participants
Incyclix Bio
View Study Details
RecruitingDetroit, MICHIGANNCT06590857

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs....

124 participants
RayzeBio, Inc.
View Study Details
RecruitingDetroit, MICHIGANNCT05386108

Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-pos...

68 participants
Stemline Therapeutics, Inc.
View Study Details
RecruitingDetroit, MICHIGANNCT05573126

Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

The aim of this study is to identify the optimal dose for Vosilasarm (EP0062) as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, an...

60 participants
Ellipses Pharma
View Study Details

About Breast Cancer Clinical Trials in Detroit

Breast cancer is a disease in which cells in the breast grow out of control. It is the most common cancer in women worldwide and can also occur in men. Treatment options include surgery, radiation, chemotherapy, hormone therapy, and targeted therapies.

There are currently 9 breast cancer clinical trials recruiting participants in Detroit, MICHIGAN. These studies are seeking a combined 2,910 participants. Research is being sponsored by Hoffmann-La Roche, Celcuity Inc, AstraZeneca and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Breast Cancer Clinical Trials in Detroit — FAQ

Are there breast cancer clinical trials in Detroit?

Yes, there are 9 breast cancer clinical trials currently recruiting in Detroit, MICHIGAN. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Detroit?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Detroit research site will contact you about next steps.

Are clinical trials in Detroit free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Detroit studies also compensate for your time and travel.

What breast cancer treatments are being tested?

The 9 active trials in Detroit are testing new therapies including novel drugs, biologics, and treatment approaches for breast cancer.

Data updated March 2, 2026 from ClinicalTrials.gov